Business
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant
– Gavel brings highly relevant CAR T experience from Legend Biotech where he led the launch and commercialization of CARVYKTI® from 2018 until 2025 – PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced the appointment of Steve Gavel as Chief Commercial Officer, effective i
About this update from Cabaletta Bio, Inc.
[{"type":"image","alt":"Cabaletta Bio","displaySize":"","headline":null,"caption":"Cabaletta Bio","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":40,"url":"https://media.zenfs.com/en/globenewswire.com/f565214a2c1c703d1ed00c6d6b50d1de"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hszKHjsTAmj809exeTCP.w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTU2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/f565214a2c1c703d1ed00c6d6b50d1de","width":300,"height":40}},"lazy":false},{"type":"text","content":"– Gavel brings highly relevant CAR T experience from Legend Biotech where he led the launch and commercialization of CARVYKTI® from 2018 until 2025 –","length":149,"tagName":"p"},{"type":"text","content":"PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced the appointment of Steve Gavel as Chief Commercial Officer, effective immediately. In his role, Mr. Gavel will join the leadership team and will lead all aspects of global commercial strategy and execution for rese-cel (resecabtagene autoleucel, formerly CABA-201), for which the Company anticipates its first Biologics License Application (BLA) submission in myositis in 2027, as well as potential future pipeline opportunities.","length":708,"tagName":"p"},{"type":"text","content":"“Steve is an outstanding leader with a track record of success launching and commercializing cellular therapies. His extensive cell therapy experience will enhance our efforts to maximize the value of rese-cel for patients, payers and providers,” said Steven Nichtberger, M.D., Chief Executive Officer of Cabaletta Bio. “We are confident Steve’s leadership will attract a world-class team to prepare for and to execute the potential launch of rese-cel.”","length":453,"tagName":"p"},{"type":"text","content":"Prior to joining Cabaletta, from 2018 to 2025, Mr. Gavel was Senior Vice President, Global Cell Therapy Commercial Development at Legend Biotech reporting to the CEO, where he created and scaled its commercial organization and led implementation of all CAR T logistics and management of the leading CAR T centers in the U.S., in partnership with Johnson & Johnson, to succ...